Immatics NV (IMTX)

Nov 18, 2024, 7:00 AM EST - 2 months ago

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

Nov 8, 2024, 5:00 PM EST - 2 months ago

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Oct 11, 2024, 9:11 PM EDT - 3 months ago

Immatics: A Promising TCR Pipeline

Oct 10, 2024, 8:50 PM EDT - 3 months ago

Immatics Announces Pricing of $150 Million Public Offering

Oct 10, 2024, 1:33 PM EDT - 3 months ago

Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?

Oct 10, 2024, 7:30 AM EDT - 3 months ago

Immatics Announces Proposed $150 Million Public Offering

Oct 10, 2024, 6:30 AM EDT - 3 months ago

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Oct 4, 2024, 9:00 AM EDT - 3 months ago

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Sep 16, 2024, 5:25 AM EDT - 4 months ago

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

Sep 6, 2024, 7:00 AM EDT - 4 months ago

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Aug 13, 2024, 7:00 AM EDT - 5 months ago

Immatics Announces Second Quarter 2024 Financial Results and Business Update

May 14, 2024, 7:00 AM EDT - 8 months ago

Immatics Announces First Quarter 2024 Financial Results and Business Update

Apr 27, 2024, 10:32 AM EDT - 9 months ago

Immatics: Big Pharma Partners, Intriguing Catalysts Make Buy Case

Mar 21, 2024, 7:00 AM EDT - 10 months ago

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Feb 3, 2024, 7:56 AM EST - 1 year ago

Immatics: Pioneering TCR Therapies In The Fight Against Cancer

Jan 17, 2024, 8:30 PM EST - 1 year ago

Immatics Announces Pricing of $175 Million Public Offering

Jan 17, 2024, 4:01 PM EST - 1 year ago

Immatics Announces Proposed Public Offering

Nov 14, 2023, 7:00 AM EST - 1 year ago

Immatics Announces Third Quarter 2023 Financial Results and Business Update

Nov 8, 2023, 7:00 AM EST - 1 year ago

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Oct 24, 2023, 7:00 AM EDT - 1 year ago

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

Oct 9, 2023, 1:33 AM EDT - 1 year ago

Analyzing Immatics' Multi-Faceted Investment Case

Sep 12, 2023, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

PLX

Sep 11, 2023, 8:59 AM EDT - 1 year ago

Immatics shares rise on Moderna cancer collaboration

MRNA

Sep 11, 2023, 7:32 AM EDT - 1 year ago

Moderna, Immatics to work jointly on cancer vaccines

MRNA

Sep 11, 2023, 7:00 AM EDT - 1 year ago

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

MRNA

Sep 11, 2023, 7:00 AM EDT - 1 year ago

Moderna & Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

MRNA

Aug 17, 2023, 7:00 AM EDT - 1 year ago

Immatics Announces Second Quarter 2023 Financial Results and Business Update

Aug 10, 2023, 7:00 AM EDT - 1 year ago

Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

Jul 24, 2023, 6:21 PM EDT - 1 year ago

Immatics: Additional Gains Possible Q4 Of 2023 With Data Update Of IMA203

Jul 24, 2023, 10:00 AM EDT - 1 year ago

Immatics Is Increasingly Becoming Interesting

Jul 24, 2023, 7:56 AM EDT - 1 year ago

Immatics shares jump after investment from Bristol Myers Squibb

BMY

Jul 24, 2023, 7:00 AM EDT - 1 year ago

Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb

May 16, 2023, 7:00 AM EDT - 1 year ago

Immatics Announces First Quarter 2023 Financial Results and Business Update

May 2, 2023, 7:00 AM EDT - 1 year ago

Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME

May 1, 2023, 7:00 AM EDT - 1 year ago

Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration

Mar 21, 2023, 7:31 AM EDT - 1 year ago

Immatics Announces Full Year 2022 Financial Results and Corporate Update

Nov 17, 2022, 7:00 AM EST - 2 years ago

Immatics Announces Third Quarter 2022 Financial Results and Business Update

Oct 10, 2022, 7:37 AM EDT - 2 years ago

Immatics Announces $110 Million Underwritten Offering of Ordinary Shares

Oct 10, 2022, 7:36 AM EDT - 2 years ago

Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME

Sep 10, 2022, 3:06 AM EDT - 2 years ago

Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

Aug 23, 2022, 7:00 AM EDT - 2 years ago

Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME

Aug 9, 2022, 7:00 AM EDT - 2 years ago

Immatics Announces Second Quarter 2022 Financial Results and Business Update

Jul 24, 2022, 9:46 AM EDT - 2 years ago

Volume Breakout Report: July 23, 2022 (Technical Analysis)

JAKK TAIT CECO

Jun 3, 2022, 6:28 PM EDT - 2 years ago

Why you should consider buying and accumulating Immatics N.V.

Jun 2, 2022, 7:44 AM EDT - 2 years ago

Bristol Myers Squibb, Immatics expand CAR-T agreement

BMY

Jun 2, 2022, 7:05 AM EDT - 2 years ago

Immatics Announces First Quarter 2022 Financial Results and Business Update

Jun 2, 2022, 6:59 AM EDT - 2 years ago

Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs

BMY

May 18, 2022, 7:00 AM EDT - 2 years ago

Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors

May 10, 2022, 7:00 AM EDT - 2 years ago

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

Mar 23, 2022, 7:00 AM EDT - 3 years ago

Immatics Announces Full Year 2021 Financial Results and Corporate Update